The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Tumor-reactive antibodies evolve from non-binding and autoreactive precursors
Open accessAbstract
The tumor microenvironment hosts antibody-secreting cells (ASCs) associated with a favorable prognosis in several types of cancer. Patient-derived antibodies have diagnostic and therapeutic potential; yet, it remains unclear how antibodies gain autoreactivity and target tumors. Here, we found that somatic hypermutations (SHMs) promote antibody antitumor reactivity against surface autoantigens in high-grade serous ovarian carcinoma (HGSOC). Patient-derived tumor cells were frequently coated with IgGs. Intratumoral ASCs in HGSOC were both mutated and clonally expanded and produced tumor-reactive antibodies that targeted MMP14, which is abundantly expressed on the tumor cell surface. The reversion of monoclonal antibodies to their germline configuration revealed two types of classes: one dependent on SHMs for tumor binding and a second with germline-encoded autoreactivity. Thus, tumor-reactive autoantibodies are either naturally occurring or evolve through an antigen-driven selection process. These findings highlight the origin and potential applicability of autoantibodies directed at surface antigens for tumor targeting in cancer patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Highly accurate protein structure prediction with AlphaFold
Jumper, J., Evans, R., Pritzel, A., Green, T., Figurnov, M., Ronneberger, O., Tunyasuvunakool, K., Bates, R., Žídek, A., Potapenko, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03819-2 · Cited by 43,764
ColabFold - Making protein folding accessible to all
Mirdita, M., Schütze, K., Moriwaki, Y., Heo, L., Ovchinnikov, S., & Steinegger, M. (2021) · doi:10.1101/2021.08.15.456425 · Cited by 9,391
QuPath: Open source software for digital pathology image analysis
Bankhead, P., Loughrey, M. B., Fernández, J. A., Dombrowski, Y., McArt, D. G., Dunne, P. D., McQuaid, S., Gray, R. T., Murray, L. J., Coleman, H. G., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-17204-5 · Cited by 8,908
PatchDock and SymmDock: servers for rigid and symmetric docking
Schneidman-Duhovny, D., Inbar, Y., Nussinov, R., & Wolfson, H. J. (2005) · Nucleic Acids Research · doi:10.1093/nar/gki481 · Cited by 3,018
B cells and tertiary lymphoid structures promote immunotherapy response
Helmink, B. A., Reddy, S. M., Gao, J., Zhang, S., Basar, R., Thakur, R., Yizhak, K., Sade-Feldman, M., Blando, J., Han, G., et al. (2020) · Nature · doi:10.1038/s41586-019-1922-8 · Cited by 2,731
Tertiary lymphoid structures improve immunotherapy and survival in melanoma
Cabrita, R., Lauss, M., Sanna, A., Donia, M., Skaarup Larsen, M., Mitra, S., Johansson, I., Phung, B., Harbst, K., Vallon-Christersson, J., et al. (2020) · Nature · doi:10.1038/s41586-019-1914-8 · Cited by 2,374
B cells are associated with survival and immunotherapy response in sarcoma
Petitprez, F., de Reyniès, A., Keung, E. Z., Chen, T. W.-W., Sun, C.-M., Calderaro, J., Jeng, Y.-M., Hsiao, L.-P., Lacroix, L., Bougoüin, A., et al. (2020) · Nature · doi:10.1038/s41586-019-1906-8 · Cited by 1,942
Victora, G. D., & Nussenzweig, M. C. (2012) · Annual Review of Immunology · doi:10.1146/annurev-immunol-020711-075032 · Cited by 1,878
Research works printed but not linked: 73
- Anderson, 2015, Autoantibody signature for the serologic detection of ovarian cancer, J. Proteome Res., 14, 578, 10.1021/pr500908n · DOI
- Andreu, 2010, FcRgamma activation regulates inflammation-associated squamous carcinogenesis, Cancer Cell, 17, 121, 10.1016/j.ccr.2009.12.019 · DOI · Paper page
- Andrusier, 2007, FireDock: fast interaction refinement in molecular docking, Proteins, 69, 139, 10.1002/prot.21495 · DOI · Paper page
- Ashkenazy, 2021, Motifier: an IgOme profiler based on peptide motifs using machine learning, J. Mol. Biol., 433, 167071, 10.1016/j.jmb.2021.167071 · DOI
- Auersperg, 2013, Ovarian surface epithelium as a source of ovarian cancers: unwarranted speculation or evidence-based hypothesis?, Gynecol. Oncol., 130, 246, 10.1016/j.ygyno.2013.03.021 · DOI
- Balicer, 2017, Digital health nation: Israel’s global big data innovation hub, Lancet, 389, 2451, 10.1016/S0140-6736(17)30876-0 · DOI
- Biram, 2019, T cell interactions with B cells during germinal center formation, a three-step model, Immunol. Rev., 288, 37, 10.1111/imr.12737 · DOI
- Biswas, 2021, IgA transcytosis and antigen recognition govern ovarian cancer immunity, Nature, 591, 464, 10.1038/s41586-020-03144-0 · DOI · Paper page
- Boland, 2019, Early disease progression and treatment discontinuation in patients with advanced ovarian cancer receiving immune checkpoint blockade, Gynecol. Oncol., 152, 251, 10.1016/j.ygyno.2018.11.025 · DOI
- Bolotin, 2017, Antigen receptor repertoire profiling from RNA-Seq data, Nat. Biotechnol., 35, 908, 10.1038/nbt.3979 · DOI · Paper page
- Bowtell, 2010, The genesis and evolution of high-grade serous ovarian cancer, Nat. Rev. Cancer, 10, 803, 10.1038/nrc2946 · DOI · Paper page
- Cathcart, 2016, Interleukin-6 increases matrix metalloproteinase-14 (MMP-14) levels via down-regulation of p53 to drive cancer progression, Oncotarget, 7, 61107, 10.18632/oncotarget.11243 · DOI
- Cho, 2015, The extracellular matrix in epithelial ovarian cancer - A piece of a puzzle, Front. Oncol., 5, 245, 10.3389/fonc.2015.00245 · DOI
- Cornaby, 2015, B cell epitope spreading: mechanisms and contribution to autoimmune diseases, Immunol. Lett., 163, 56, 10.1016/j.imlet.2014.11.001 · DOI · Paper page
- Crowley, 2016, Matrix metalloproteinase-10 is a target of T and B cell responses that correlate with synovial pathology in patients with antibiotic-refractory lyme arthritis, J. Autoimmun., 69, 24, 10.1016/j.jaut.2016.02.005 · DOI
- Cui, 2021, Neoantigen-driven B cell and CD4 T follicular helper cell collaboration promotes robust anti-tumor CD8 T cell responses, Cell, 184, 6101, 10.1016/j.cell.2021.11.007 · DOI · Paper page
- Degn, 2017, Clonal evolution of autoreactive germinal centers, Cell, 170, 913, 10.1016/j.cell.2017.07.026 · DOI
- DeNardo, 2019, Macrophages as regulators of tumour immunity and immunotherapy, Nat. Rev. Immunol., 19, 369, 10.1038/s41577-019-0127-6 · DOI · Paper page
- DeWeerdt, 2021, The origins of ovarian cancer, Nature, 600, S42, 10.1038/d41586-021-03717-7 · DOI
- Di Zenzo, 2012, Pemphigus autoantibodies generated through somatic mutations target the desmoglein-3 cis-interface, J. Clin. Invest., 122, 3781, 10.1172/JCI64413 · DOI · Paper page
- DiLillo, 2015, Fc-receptor interactions regulate both cytotoxic and immunomodulatory therapeutic antibody effector functions, Cancer Immunol. Res., 3, 704, 10.1158/2326-6066.CIR-15-0120 · DOI
- Doo, 2019, Checkpoint inhibitors in ovarian cancer: a review of preclinical data, Gynecol. Oncol. Rep., 29, 48, 10.1016/j.gore.2019.06.003 · DOI
- Freund, 2009, Phage display selection, analysis, and prediction of B cell epitopes, Curr. Protoc. Immunol., 9, 8
- Gnjatic, 2010, Seromic profiling of ovarian and pancreatic cancer, Proc. Natl. Acad. Sci. USA, 107, 5088, 10.1073/pnas.0914213107 · DOI · Paper page
- Gupta, 2015, Change-O: A toolkit for analyzing large-scale B cell immunoglobulin repertoire sequencing data, Bioinformatics, 31, 3356, 10.1093/bioinformatics/btv359 · DOI · Paper page
- Hu, 2019, Landscape of B cell immunity and related immune evasion in human cancers, Nat. Genet., 51, 560, 10.1038/s41588-018-0339-x · DOI · Paper page
- Jayson, 2014, Ovarian cancer, Lancet, 384, 1376, 10.1016/S0140-6736(13)62146-7 · DOI · Paper page
- Kaimal, 2013, Selective blockade of matrix Metalloprotease-14 with a monoclonal antibody abrogates invasion, angiogenesis, and tumor growth in ovarian cancer, Cancer Res., 73, 2457, 10.1158/0008-5472.CAN-12-1426 · DOI
- Kamel, 2010, Immunoexpression of matrix metalloproteinase-2 (MMP-2) in malignant ovarian epithelial tumours, J. Obstet. Gynaecol. Can., 32, 580, 10.1016/S1701-2163(16)34527-3 · doi:10.1016/s1701-2163(16)34527-3
- Kroeger, 2016, Tumor-infiltrating plasma cells are associated with tertiary lymphoid structures, cytolytic T-cell responses, and superior prognosis in ovarian cancer, Clin. Cancer Res., 22, 3005, 10.1158/1078-0432.CCR-15-2762 · DOI · Paper page
- Labidi-Galy, 2017, High grade serous ovarian carcinomas originate in the fallopian tube, Nat. Commun., 8, 1093, 10.1038/s41467-017-00962-1 · DOI · Paper page
- Ma, 2020, Using protein microarray to identify and evaluate autoantibodies to tumor-associated antigens in ovarian cancer, Cancer Sci., 112, 537, 10.1111/cas.14732 · DOI
- Mahmood, 2020, First-line management of advanced high-grade serous ovarian cancer, Curr. Oncol. Rep., 22, 64, 10.1007/s11912-020-00933-8 · DOI
- Maletzki, 2012, Ex-vivo clonally expanded B lymphocytes infiltrating colorectal carcinoma are of mature immunophenotype and produce functional IgG, PLoS One, 7, e32639, 10.1371/journal.pone.0032639 · DOI
- Mashiach, 2008, FireDock: A web server for fast interaction refinement in molecular docking, Nucleic Acids Res., 36, W229, 10.1093/nar/gkn186 · DOI · Paper page
- Mietzner, 2008, Autoreactive IgG memory antibodies in patients with systemic lupus erythematosus arise from nonreactive and polyreactive precursors, Proc. Natl. Acad. Sci. USA, 105, 9727, 10.1073/pnas.0803644105 · DOI · Paper page
- Milne, 2008, Tumor-infiltrating T cells correlate with NY-ESO-1-Specific autoantibodies in ovarian cancer, PLoS One, 3, e3409, 10.1371/journal.pone.0003409 · DOI
- Montfort, 2017, A strong B-cell response is part of the immune landscape in human high-grade serous ovarian metastases, Clin. Cancer Res., 23, 250, 10.1158/1078-0432.CCR-16-0081 · DOI · Paper page
- Mose, 2016, Assembly-based inference of B-cell receptor repertoires from short read RNA sequencing data with V’DJer, Bioinformatics, 32, 3729, 10.1093/bioinformatics/btw526 · DOI
- Moss, 2009, Ovarian cancer cell detachment and multicellular aggregate formation are regulated by membrane type 1 matrix metalloproteinase: a potential role in I.p. metastatic dissemination, Cancer Res., 69, 7121, 10.1158/0008-5472.CAN-08-4151 · DOI
- Nelson, 2010, CD20+ B cells: the other tumor-infiltrating lymphocytes, J. Immunol., 185, 4977, 10.4049/jimmunol.1001323 · DOI · Paper page
- Nishijima, 2004, Autoantibody against matrix metalloproteinase-3 in patients with systemic sclerosis, Clin. Exp. Immunol., 138, 357, 10.1111/j.1365-2249.2004.02615.x · DOI
- Nzula, 2003, Antigen-driven clonal proliferation, somatic hypermutation, and selection of B lymphocytes infiltrating human ductal breast carcinomas, Cancer Res., 63, 3275
- O Donnell, 2014, The use of ovarian cancer cells from patients undergoing surgery to generate primary cultures capable of undergoing functional analysis, PLoS One, 9, e90604, 10.1371/journal.pone.0090604 · DOI
- Piccoli, 2015, Neutralization and clearance of GM-CSF by autoantibodies in pulmonary alveolar proteinosis, Nat. Commun., 6, 7375, 10.1038/ncomms8375 · DOI
- Pitzalis, 2014, Ectopic lymphoid-like structures in infection, cancer and autoimmunity, Nat. Rev. Immunol., 14, 447, 10.1038/nri3700 · DOI · Paper page
- Prigent, 2016, Scarcity of autoreactive human blood IgA+ memory B cells, Eur. J. Immunol., 46, 2340, 10.1002/eji.201646446 · DOI
- Ramalingam, 2016, Morphologic, immunophenotypic, and molecular features of epithelial ovarian cancer, Oncology (Williston Park), 30, 166
- Ran, 1976, Tumor-bound immunoglobulins. Evidence for the in vivo coating of tumor cells by potentially cytotoxic anti-tumour antibodies, Int. J. Cancer, 17, 90, 10.1002/ijc.2910170113 · DOI
- Rao, 1988, Detection of human ovarian tumor-associated antigens by antibodies isolated from ovarian carcinoma ascitic fluid, Am. J. Obstet. Gynecol., 159, 94, 10.1016/0002-9378(88)90500-5 · doi:10.1016/0002-9378(88)90500-5
- Sakata, 2000, Expression of matrix metalloproteinases (MMP-2, MMP-9, MT1-MMP) and their inhibitors (TIMP-1, TIMP-2) in common epithelial tumors of the ovary, Int. J. Oncol., 17, 673
- Sato, 2003, Function blocking autoantibodies Against matrix metalloproteinase-1 in patients with systemic sclerosis, J. Invest. Dermatol., 120, 542, 10.1046/j.1523-1747.2003.12097.x · DOI
- Saul, 2016, IgG subclass switching and clonal expansion in cutaneous melanoma and normal skin, Sci. Rep., 6, 29736, 10.1038/srep29736 · DOI
- Schroeder, 2013, The role of somatic hypermutation in the generation of pathogenic antibodies in SLE, Autoimmunity, 46, 121, 10.3109/08916934.2012.748751 · DOI
- Sharonov, 2020, B cells, plasma cells and antibody repertoires in the tumour microenvironment, Nat. Rev. Immunol., 20, 294, 10.1038/s41577-019-0257-x · DOI · Paper page
- Silburn, 1984, Demonstration of tumor-associated immunoglobulin G isolated from immune complexes in ascitic fluid of ovarian cancer, Diagn. Immunol., 2, 30
- Tiller, 2008, Efficient generation of monoclonal antibodies from single human B cells by single cell RT-PCR and expressionvector cloning, J. Immunol. Methods, 329, 112, 10.1016/j.jim.2007.09.017 · DOI · Paper page
- Tiller, 2007, Autoreactivity in human IgG+ memory B cells, Immunity, 26, 205, 10.1016/j.immuni.2007.01.009 · DOI · Paper page
- Udi, 2013, Unraveling hidden allosteric regulatory sites in structurally homologues metalloproteases, J. Mol. Biol., 425, 2330, 10.1016/j.jmb.2013.04.009 · DOI
- Uppendahl, 2017, Natural killer cell-based immunotherapy in gynecologic malignancy: a review, Front. Immunol., 8, 1825, 10.3389/fimmu.2017.01825 · DOI
- Vinuesa, 2009, Dysregulation of germinal centres in autoimmune disease, Nat. Rev. Immunol., 9, 845, 10.1038/nri2637 · DOI · Paper page
- Vos, 2021, The role of MMP-14 in ovarian cancer: a systematic review, J. Ovarian Res., 14, 1
- Vos, 2016, MMP-14 and CD44 in epithelial-to-mesenchymal transition (EMT) in ovarian cancer, J. Ovarian Res., 9, 53, 10.1186/s13048-016-0262-7 · DOI
- Wang, 2021, Diverse functional autoantibodies in patients with COVID-19, medRxiv
- Wardemann, 2003, Predominant autoantibody production by early human B cell precursors, Science, 301, 1374, 10.1126/science.1086907 · DOI · Paper page
- Webb, 2021, Tissues: the unexplored frontier of antibody mediated immunity, Curr. Opin. Virol., 47, 52, 10.1016/j.coviro.2021.01.001 · DOI
- Wieland, 2019, Fc receptors in antimicrobial protection, Curr. Top. Microbiol. Immunol., 423, 119
- Wieland, 2021, Defining HPV-specific B cell responses in patients with head and neck cancer, Nature, 597, 274, 10.1038/s41586-020-2931-3 · DOI · Paper page
- Witz, 1977, Tumor-bound immunoglobulins: in situ expressions of humoral immunity, Adv. Cancer Res., 25, 95, 10.1016/S0065-230X(08)60633-8 · DOI
- Yaari, 2012, Quantifying selection in high-throughput immunoglobulin sequencing data sets, Nucleic Acids Res., 40, e134, 10.1093/nar/gks457 · DOI · Paper page
- Yang, 2021, Shared B cell memory to coronaviruses and other pathogens varies in human age groups and tissues, Science, 372, 738, 10.1126/science.abf6648 · DOI
- Ye, 2013, IgBLAST: an immunoglobulin variable domain sequence analysis tool, Nucleic Acids Res., 41, W34, 10.1093/nar/gkt382 · DOI · Paper page
- Zaenker, 2016, Autoantibody production in cancer—the humoral immune response toward autologous antigens in cancer patients, Autoimmun. Rev., 15, 477, 10.1016/j.autrev.2016.01.017 · DOI · Paper page
Cited by
Fridman, W. H., Meylan, M., Petitprez, F., Sun, C.-M., Italiano, A., & Sautès-Fridman, C. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00619-z · Cited by 657
de Almeida, L. G. N., Thode, H., Eslambolchi, Y., Chopra, S., Young, D., Gill, S., Devel, L., & Dufour, A. (2022) · Pharmacological Reviews · doi:10.1124/pharmrev.121.000349 · Cited by 535
Tertiary lymphoid structures and B cells: An intratumoral immunity cycle
Fridman, W. H., Meylan, M., Pupier, G., Calvez, A., Hernandez, I., & Sautès-Fridman, C. (2023) · Immunity · doi:10.1016/j.immuni.2023.08.009 · Cited by 326
The roles of tertiary lymphoid structures in chronic diseases
Sato, Y., Silina, K., van den Broek, M., Hirahara, K., & Yanagita, M. (2023) · Nature Reviews Nephrology · doi:10.1038/s41581-023-00706-z · Cited by 320
Tertiary lymphoid structures in anticancer immunity
Teillaud, J.-L., Houel, A., Panouillot, M., Riffard, C., & Dieu-Nosjean, M.-C. (2024) · Nature Reviews Cancer · doi:10.1038/s41568-024-00728-0 · Cited by 293
Metadata
- Authors
- Mazor, R. D., Nathan, N., Gilboa, A., Stoler-Barak, L., Moss, L., Solomonov, I., Hanuna, A., Divinsky, Y., Shmueli, M. D., Hezroni, H., Zaretsky, I., Mor, M., Golani, O., Sabah, G., Jakobson-Setton, A., Yanichkin, N., Feinmesser, M., Tsoref, D., Salman, L., Yeoshoua, E., Peretz, E., Erlich, I., Cohen, N. M., Gershoni, J. M., Freund, N., Merbl, Y., Yaari, G., Eitan, R., Sagi, I., & Shulman, Z.
- Venue
- Cell
- Publisher
- Elsevier BV
- Published
- 2022-03
- Volume
- 185
- Issue
- 7
- Pages
- 1208-1222.e21
- ISSN
- 0092-8674 (ISSN-L)
- OpenAlex
- W4221041063
- Cited by
- 177
- References
- 8
- FWCI
- 10.55
- Type
- journal article
- Language
- en
- Open access
- bronze
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- www.elsevier.com/open-access/userlicense/1.0/ (vor, 395 d)
- doi.org/10.15223/policy-017 (stm-asf)
- doi.org/10.15223/policy-037 (stm-asf)
- doi.org/10.15223/policy-012 (stm-asf)
- doi.org/10.15223/policy-029 (stm-asf)
- doi.org/10.15223/policy-004 (stm-asf)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Tumor-reactive antibodies evolve from non-binding and autoreactive precursors. https://app.cochat.ai/papers/10.1016/j.cell.2022.02.012
- The paper
- Mazor, R. D., Nathan, N., Gilboa, A., Stoler-Barak, L., Moss, L., Solomonov, I., Hanuna, A., Divinsky, Y., Shmueli, M. D., Hezroni, H., Zaretsky, I., Mor, M., Golani, O., Sabah, G., Jakobson-Setton, A., Yanichkin, N., Feinmesser, M., Tsoref, D., Salman, L., . . . Shulman, Z. (2022). Tumor-reactive antibodies evolve from non-binding and autoreactive precursors. Cell. https://doi.org/10.1016/j.cell.2022.02.012
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.